S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
NASDAQ:HRTX

Heron Therapeutics (HRTX) Stock Forecast, Price & News

$1.24
+0.05 (+4.20%)
(As of 06/9/2023 ET)
Compare
Today's Range
$1.20
$1.32
50-Day Range
$1.11
$2.88
52-Week Range
$1.07
$5.62
Volume
3.17 million shs
Average Volume
2.22 million shs
Market Capitalization
$148.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Heron Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
504.8% Upside
$7.50 Price Target
Short Interest
Bearish
18.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.66mentions of Heron Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.90) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

469th out of 988 stocks

Pharmaceutical Preparations Industry

223rd out of 481 stocks


HRTX stock logo

About Heron Therapeutics (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

Heron Therapeutics (NASDAQ: HRTX)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Heron Therapeutics (HRTX) Gets a Buy from Needham
Analyst Expectations for Heron Therapeutics's Future
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Earnings Preview: Heron Therapeutics
Why Shares of Heron Therapeutics Jumped Thursday
See More Headlines

HRTX Price History

HRTX Company Calendar

Last Earnings
3/23/2023
Today
6/10/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
302
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+504.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-182,020,000.00
Net Margins
-132.57%
Pretax Margin
-132.57%
Return on Equity
-21,127.62%

Debt

Sales & Book Value

Annual Sales
$107.67 million
Book Value
$0.11 per share

Miscellaneous

Free Float
113,705,000
Market Cap
$148.44 million
Optionable
Optionable
Beta
0.92

Social Links


Key Executives

  • Craig A. Collard
    Chief Executive Officer & Director
  • David L. Szekeres
    Chief Operating Officer & Executive Vice President
  • Thomas B. Ottoboni
    Chief Scientific Officer & SVP-Pharmaceutical
  • Chris M. Storgard
    Chief Medical Officer
  • Lisa Peraza
    Chief Accounting Officer & Vice President













HRTX Stock - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 504.8% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2023?

Heron Therapeutics' stock was trading at $2.50 at the beginning of 2023. Since then, HRTX stock has decreased by 50.4% and is now trading at $1.24.
View the best growth stocks for 2023 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. Heron Therapeutics had a negative net margin of 132.57% and a negative trailing twelve-month return on equity of 21,127.62%. The company's revenue was up 44.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.54) earnings per share.

What ETFs hold Heron Therapeutics' stock?

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Simplify Propel Opportunities ETF (SURI).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.88%), JPMorgan Chase & Co. (5.92%), Great Point Partners LLC (4.88%), Palisade Capital Management LP (3.33%), ArrowMark Colorado Holdings LLC (2.80%) and State Street Corp (2.14%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $1.24.

How much money does Heron Therapeutics make?

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $148.44 million and generates $107.67 million in revenue each year. The biotechnology company earns $-182,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Heron Therapeutics have?

The company employs 302 workers across the globe.

Does Heron Therapeutics have any subsidiaries?
The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More
How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.

This page (NASDAQ:HRTX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -